Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead

Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resis...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical research 2018-11, Vol.35 (11), p.213-22, Article 213
Main Authors: Grotz, Estefania, Tateosian, Nancy, Amiano, Nicolas, Cagel, Maximiliano, Bernabeu, Ezequiel, Chiappetta, Diego A., Moretton, Marcela A.
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Animals
Antitubercular agents
Antitubercular Agents - administration & dosage
Antitubercular Agents - chemistry
Antitubercular Agents - therapeutic use
B cells
Biochemistry
Biomedical and Life Sciences
Biomedical Engineering and Bioengineering
Biomedicine
Development and progression
Drug delivery
Drug Delivery Systems - methods
Drug Discovery - methods
Drug resistance
Drug Resistance, Bacterial
Economic impact
Expert Review
Health aspects
HIV
Human immunodeficiency virus
Humans
Liposomes - chemistry
Medical Law
Micelles
Mycobacterium tuberculosis - drug effects
Nanomedicine - methods
Nanomedicine for Infectious Diseases
Nanoparticles - chemistry
Nanotechnology
Nanotechnology - methods
Patient compliance
Pharmacology/Toxicology
Pharmacy
Tuberculosis
Tuberculosis - drug therapy
Tuberculosis - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tuberculosis (TB) remains as the second most-deadly infection right behind the HIV/AIDS. Actually, in 2016, TB incidence was estimated in 10.4 million cases. Although an efficient and low-cost TB pharmacotherapy has been available for the last 50 years, the development of multi- and extra-drug-resistant Mycobacterium tuberculosis (Mtb) strains has put on the spot the necessity of improved TB regimens. In this framework, this review article presents the main relevant research outcomes of nanotechnology in TB. The novel delivery systems for antituberculosis drugs have been discussed. Moreover, the active-targeted nanomedicines to the Mtb reservoirs enlighten the possibility to eradicate low-replicant mycobacteria and diminish latent TB. Finally, we present an overview of the TB socio-economic impact and the cost-related features of TB regimens associated with the use of nanoformulations.
ISSN:0724-8741
1573-904X
DOI:10.1007/s11095-018-2497-z